2025ÄêÃÀ¹ú°©Ö¢Ñо¿Ð»á£¨AACR£©Äê»á½«ÓÚ4ÔÂ25-30ÈÕÔÚÃÀ¹úÖ¥¼Ó¸çÕÙ¿ª¡£¸Ã»áÒéÊÇÈ«ÇòÖ×ÁöѧÁìÓò×î¾ßÓ°ÏìÁ¦µÄѧÊõÊ¢»áÖ®Ò»¡£µÏÍþÖÆµÏÍþ¹ú¼ÊÔÑд´ÐµÏÍþ¹ú¼Ê°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáÆ¬£©AENEAS2£¨ÁªºÏ»¯ÁÆÓÃÓÚÍíÆÚ·ÇСϸ°û·Î°©Ò»ÏßÖÎÁÆ£¬HS-10296-306£©¼°ARTS£¨·ÇСϸ°û·Î°©Êõºó¸¨ÖúÖÎÁÆ£¬HS-10296-302£©Á½Ïî¢óÆÚ¹Ø¼üÁÙ´²Ñо¿¾ùÒÔ¿ÚÍ·±¨¸æÐÎʽÈëÑ¡£¬ÕâÒ²ÊÇÏà¹ØÑо¿Êý¾ÝµÄÈ«ÇòÊ״η¢²¼£¬½«ÔÚ¹ú¼Ê¶¥¼âѧÊõÎę̀ÔÙ¶ÈÕ¹ÏÖÖйúÔÑÐʵÁ¦¡£
AENEAS2Ñо¿£¨HS-10296-306£©
±êÌ⣺
Aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations (AENEAS2)
±¨¸æÈË£º
ÉϺ£½»Í¨´óѧҽѧԺ¸½ÊôÐØ¿ÆÒ½Ôº¡¢ÉϺ£Êзβ¿Ö×ÁöÁÙ´²Ò½Ñ§ÖÐÐÄ Â½Ë´ ½ÌÊÚ
±¨¸æÀàÐÍ£º
È«Ìå´ó»á¿ÚÍ·±¨¸æ£¨Plenary Oral Presentation£©
±¨¸æÊ±¼ä£º
2025Äê4ÔÂ28ÈÕ 10:15 AM- 12:15 PM£¨µ±µØÊ±¼ä£©
µØµã£º
ÃÀ¹ú Ö¥¼Ó¸ç
ARTSÑо¿£¨HS-10296-302£©
±êÌ⣺
Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS)
±¨¸æÈË£º
¼ªÁÖÊ¡Ö×ÁöÒ½Ôº¶ñÐÔÖ×ÁöÁÙ´²Ñо¿Ò»Ì廯ÕïÁÆÖÐÐÄ¡¢¼ªÁÖÊ¡°©Ö¢ÖÐÐÄ ³ÌÓ± ½ÌÊÚ
±¨¸æÀàÐÍ£º
רÌâÑÐÌÖ»á¿ÚÍ·±¨¸æ£¨Minisymposium Oral Presentation£©
±¨¸æÊ±¼ä£º
2025Äê4ÔÂ28ÈÕ 2:30 PM - 4:30 PM£¨µ±µØÊ±¼ä£©
µØµã£º
ÃÀ¹ú Ö¥¼Ó¸ç
ÃÀ¹ú°©Ö¢Ñо¿Ð»á£¨American Association for Cancer Research, AACR£©³ÉÁ¢ÓÚ1907Ä꣬ÊÇÊÀ½çÉÏ´´Á¢×îÔç¡¢¹æÄ£×î´óµÄרעÓÚ°©Ö¢Ñо¿µÄ¿ÆÑ§×éÖ¯¡£AACRÄê»áÊÇÊÀ½çÉϹæÄ£×î´óµÄ°©Ö¢Ñо¿»áÒéÖ®Ò»£¬Ã¿Äê¶¼»áÎüÒýÀ´×ÔÊÀ½ç¸÷µØµÄ½ü20000ÃûרҵÈËÊ¿³öϯ¡£2025ÄêµÚ116½ìAACRÄê»á½«ÓÚ2025Äê4ÔÂ25-30ÈÕÔÚÃÀ¹úÖ¥¼Ó¸ç¾ÙÐС£
×÷ΪÖйúÊ׸öÔÑÐÈý´úEGFR-TKI£¬°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáÆ¬£©´´ÐÂÐÔµØÒýÈë»·±û»ù½á¹¹£¬¾ßÓÐÁ¼ºÃµÄÖ¬ÈÜÐÔºÍÎȶ¨ÐÔ£¬ÄܸüºÃµØÍ¸¹ýѪÄÔÆÁÕÏ£¬ÇÒ²»Á¼·´Ó¦·¢ÉúÂʵ͡£Ä¿Ç°£¬°¢ÃÀÀÖ?ÒÑÓÐÈýÏîÊÊÓ¦Ö¢»ñÅúÉÏÊУ¬·Ö±ðÊÇ£º¶þÏßÖÎÁƼÈÍù¾EGFR-TKIÖÎÁƽøÕ¹£¬ÇÒT790MÍ»±äÑôÐԵľֲ¿ÍíÆÚ»ò×ªÒÆÐÔNSCLC»¼Õߣ¬Ò»ÏßÖÎÁƾßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äÑôÐԵľֲ¿ÍíÆÚ»ò×ªÒÆÐÔNSCLC³ÉÈË»¼Õߣ¬ÒÔ¼°º¬²¬¸ùÖÎÐÔ·Å»¯Áƺóδ³öÏÖ¼²²¡½øÕ¹µÄ²»¿ÉÇгýµÄ¾Ö²¿ÍíÆÚEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄNSCLC»¼ÕßÖÎÁÆ¡£
µÏÍþÖÆµÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖÆµÏÍþ¹ú¼ÊÆóÒµ£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁĿǰ£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖÆµÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖÆµÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖØµã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖÆµÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£
¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£
ÉùÃ÷£º
1¡¢±¾¹«¸æ½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£
2¡¢µÏÍþÖÆµÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍÆ¼ö¡£
3¡¢±¾¹«¸æÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£
4¡¢ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£
ǰհÐÔ˵Ã÷
±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æä¸½Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆÎª¡°µÏÍþÖÆµÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖÆµÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£
±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄܰüÀ¨ÓëµÏÍþÖÆµÏÍþ¹ú¼ÊÒµÎñºÍ²úƷǰ¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆÚºÍ²ßÂÔÏà¹ØµÄǰհÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍÆ²âÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿ÆÑ§¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËØºÜ¶à¶¼ÊǵÏÍþÖÆµÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊÆ²»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£
µÏÍþÖÆµÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖÆµÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζÊ¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄǰհÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£